Patient characteristics at time of infection onset
| Characteristic . | N (%)∗ . |
|---|---|
| Sex† | |
| Male | 37 (66) |
| Female | 19 (34) |
| Age, median (range) | 62.5 (21-80) |
| HCT recipient | 25 (43.1) |
| Underlying disease† | |
| AML | 27 (45) |
| ALL | 9 (20) |
| MDS | 8 (14.3) |
| Lymphoma | 8 (14.3) |
| Other‡ | 4 (7.1) |
| Neutropenia§ | 44 (75.9) |
| Profound neutropeniaǁ | 38 (65.5) |
| Empiric anti-Pseudomonal antibiotic | |
| Cefepime | 37 (63.7) |
| Piperacillin-tazobactam | 15 (26) |
| Meropenem | 3 (5.2) |
| Ceftolozane-tazobactam | 3 (5.2) |
| Adjunctive empirical tobramycin¶ | 11 (19) |
| Antipseudomonal antibiotic susceptibility | |
| Cefepime | 54 (93.1) |
| Piperacillin-tazobactam | 50 (86.2) |
| Meropenem | 19 (34) |
| MDR P. aeruginosa | 8 (13.8) |
| AEAT | 51(87.9) |
| Pneumonia | 18 (31.0) |
| Copathogen | 14 (24.1) |
| Steroid receipt# | 21 (36.2) |
| exoU+ genotype | 18 (31) |
| Characteristic . | N (%)∗ . |
|---|---|
| Sex† | |
| Male | 37 (66) |
| Female | 19 (34) |
| Age, median (range) | 62.5 (21-80) |
| HCT recipient | 25 (43.1) |
| Underlying disease† | |
| AML | 27 (45) |
| ALL | 9 (20) |
| MDS | 8 (14.3) |
| Lymphoma | 8 (14.3) |
| Other‡ | 4 (7.1) |
| Neutropenia§ | 44 (75.9) |
| Profound neutropeniaǁ | 38 (65.5) |
| Empiric anti-Pseudomonal antibiotic | |
| Cefepime | 37 (63.7) |
| Piperacillin-tazobactam | 15 (26) |
| Meropenem | 3 (5.2) |
| Ceftolozane-tazobactam | 3 (5.2) |
| Adjunctive empirical tobramycin¶ | 11 (19) |
| Antipseudomonal antibiotic susceptibility | |
| Cefepime | 54 (93.1) |
| Piperacillin-tazobactam | 50 (86.2) |
| Meropenem | 19 (34) |
| MDR P. aeruginosa | 8 (13.8) |
| AEAT | 51(87.9) |
| Pneumonia | 18 (31.0) |
| Copathogen | 14 (24.1) |
| Steroid receipt# | 21 (36.2) |
| exoU+ genotype | 18 (31) |
The time of infection onset is defined as the date of first infected blood or BALF culture.
AEAT, appropriate empirical antibiotic therapy; AML, acute myeloid leukemia; ALL, acute lymphocytic leukemia; MDS, myelodysplastic syndrome; MDR, multidrug resistant.
Total N = 58 episodes, except where indicated.
Out of 56 unique patients.
Multiple myeloma (n = 3); acute promyelocytic leukemia (n = 1).
Absolute neutrophil count < 500 cells per mm3.
Absolute neutrophil count < 100 cells per mm3.
Used in combination with an antipseudomonal β-lactam or meropenem.
Receipt of steroids at any dose at the time of infection onset.